Clinical Trial Detail

NCT ID NCT03341936
Title Adjuvant Nivolumab and Lirilumab in Patients With Relapsed, Resectable Squamous Cell Carcinoma of the Head and Neck
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications

laryngeal squamous cell carcinoma

oropharynx cancer

nasopharynx carcinoma

head and neck squamous cell carcinoma

oral squamous cell carcinoma

hypopharynx cancer

Therapies

Lirilumab + Nivolumab

Age Groups: adult senior

No variant requirements are available.